Search

Ionis Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

44.93 -4.49

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

44.61

Massimo

47.31

Metriche Chiave

By Trading Economics

Entrata

-22M

-115M

Vendite

22M

268M

EPS

-0.7

Margine di Profitto

-42.787

Dipendenti

1,480

EBITDA

-37M

-105M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+87.95% upside

Dividendi

By Acuity

Utili prossimi

28 ott 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-700M

8.5B

Apertura precedente

49.42

Chiusura precedente

44.93

Notizie sul Sentiment di mercato

By Acuity

61%

39%

277 / 339 Classifica in Healthcare

Ionis Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 set 2026, 20:08 UTC

Social Media
Macro Event

Ionis Pharmaceuticals shares fell amid challenges from its failed Phase 3 ATTR partnership, erasing about $4.63 billion in market value.

15 set 2026, 23:01 UTC

Ionis Pharmaceuticals shares are trading higher in after-market hours, despite a broader market decline indicated by a sharp drop in the Empire State Manufacturing Index.

14 set 2026, 23:16 UTC

Ionis Pharmaceuticals Inc. shares are higher in after-market trading, though still below the 20-day moving average after six consecutive sessions of declines.

11 set 2026, 23:56 UTC

News

Ionis Pharmaceuticals received FDA approval for ZANVASTRO. Shares are higher in after-market trading, reflecting positive sentiment despite a setback in a partnered trial.

10 set 2026, 19:16 UTC

News

Ionis Pharmaceuticals shares are lower as HC Wainwright cuts the price target from $115.00 to $100.00 while maintaining a "buy" rating.

9 set 2026, 22:51 UTC

Ionis Pharmaceuticals shares are lower in after-market hours. Broader market trends reflect concerns over rising crude oil prices exceeding $100 amid Middle East tensions.

8 set 2026, 23:41 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market trading, reversing earlier gains and reflecting overall weakness without any specific news to explain the decline.

5 set 2026, 00:05 UTC

News

Ionis Pharmaceuticals shares are lower in after-market hours following Novartis' announcement that the pelacarsen Phase 3 study did not meet its primary endpoint.

4 set 2026, 23:02 UTC

News

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

3 set 2026, 22:02 UTC

News

Ionis Pharmaceuticals shares are higher in after-hours trading following FDA approval for Zanvastro, the first treatment for Alexander disease.

2 set 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting notable selling pressure since Wednesday's close. No specific news was identified to explain the decline.

1 set 2026, 22:01 UTC

Ionis Pharmaceuticals Inc shares are trading higher in after-market hours, reversing a trend of five consecutive lower sessions. No specific news was identified.

31 ago 2026, 19:56 UTC

News

Ionis Pharmaceuticals shares are lower today following negative results from a failed trial of Wainua, which did not meet its primary endpoint.

28 ago 2026, 21:01 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, continuing a trend of four consecutive daily declines despite remaining above the 20-day moving average.

27 ago 2026, 23:46 UTC

Ionis Pharmaceuticals shares traded near unchanged during after-market hours, reflecting routine activity. The stock has declined for three consecutive sessions.

26 ago 2026, 23:51 UTC

Ionis Pharmaceuticals is rising in after-market hours, reflecting broader market gains amid positive economic data on durable goods orders and inflation indicators.

25 ago 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, maintaining momentum above the 20-day moving average amid a broader market reaction to falling crude oil prices.

24 ago 2026, 23:11 UTC

Ionis Pharmaceuticals shares are higher in after-market hours following a session low. Broader market performance remains subdued amid ongoing geopolitical concerns.

22 ago 2026, 00:01 UTC

Ionis Pharmaceuticals Inc is higher in after-market trading, reflecting strength amid a broader market rebound. The stock remains above its 20-day moving average.

21 ago 2026, 22:51 UTC

Ionis Pharmaceuticals Inc shares are trading higher during after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

20 ago 2026, 20:02 UTC

News
Event

Ionis Pharmaceuticals will present new data on hypertriglyceridemia treatments at the European Society of Cardiology Congress, though shares are trading lower today.

19 ago 2026, 23:06 UTC

News

Ionis Pharmaceuticals is advancing RG-6299 into a pivotal Phase III trial for IgA nephropathy in collaboration with Roche and Chugai. Shares are higher in after-market trading.

18 ago 2026, 20:06 UTC

Ionis Pharmaceuticals Inc shares are higher, supported by strong momentum above the 20-day moving average. No specific news was identified for today's move.

17 ago 2026, 23:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Monday's close amid broader market weakness and geopolitical tensions.

14 ago 2026, 22:02 UTC

Ionis Pharmaceuticals shares are higher in after-market trading. No specific news was identified to explain the movement amid broader economic concerns.

13 ago 2026, 19:56 UTC

Ionis Pharmaceuticals Inc shares are lower today, reflecting broader market trends. First-time unemployment claims rose, but overall investor sentiment remains stable.

12 ago 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

11 ago 2026, 23:46 UTC

Ionis Pharmaceuticals shares are higher in after-market trading, reaching a high near the upper end of their one-month range. No specific news was identified.

10 ago 2026, 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours. Broader market sentiment is cautious following weaker-than-expected labor market data.

7 ago 2026, 20:03 UTC

News

Ionis Pharmaceuticals shares are higher today amid increased market volume. HC Wainwright revised Q3 2026 loss estimates, maintaining a "Buy" rating.

Confronto tra pari

Modifica del prezzo

Ionis Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

87.95% in crescita

Previsioni per 12 mesi

Media 84.278 USD  87.95%

Alto 104 USD

Basso 54 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ionis Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

16

Acquista

4

Mantieni

0

Vendi

Sentiment

By Acuity

277 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat